Regenerative Research Foundation Selected as a Winner of NIH’s Complement-ARIE Challenge
The Regenerative Research Foundation has announced that its Neural Stem Cell Institute (NSCI) has been selected as a Phase 1 winner in the National Institutes of Health’s (NIH) Complement-ARIE Reduction to Practice (RTP) Challenge. The recognition highlights NSCI’s work developing advanced human-based models that could help improve the study of neurological diseases and support the development of safer and more effective therapies.
NSCI was recognized for its proposal, “Multi-Brain Region Assembloid Combinatorial Models,” an initiative focused on creating sophisticated laboratory models that more closely reproduce the biological complexity of the human brain.
The project is based on NSCI’s expertise in generating region-specific brain organoids from human stem cells. Researchers plan to combine these specialized organoids into larger and more complex structures known as assembloids. By bringing together multiple brain regions within a single model, the approach is designed to reproduce interactions that are important for human brain development, neurological function, and disease.
The NIH’s Complement-ARIE RTP Challenge is intended to support the development and practical advancement of New Approach Methodologies, or NAMs. These technologies are being developed as complementary or alternative approaches to conventional animal testing and are intended to provide more human-relevant information during biomedical research.
The NSCI project represents one example of how human stem cell technology, organoid biology, and advanced laboratory modeling can be combined to create new tools for drug discovery and preclinical research.
Advancing Human-Relevant Research Models
Traditional preclinical research frequently relies on animal models to evaluate the potential safety and effectiveness of drug candidates before they enter clinical trials. While animal studies remain an important component of biomedical research, biological differences between animals and humans can make it difficult to accurately predict how a therapy will perform in people.
New Approach Methodologies seek to address some of these limitations by developing research systems that more directly reflect human biology.
Human-derived organoids are one such technology. These three-dimensional cellular structures can be generated from human stem cells and developed to reproduce characteristics of specific tissues or organs.
In neuroscience research, organoids can be developed to represent different regions of the human brain. However, individual brain-region organoids do not necessarily reproduce the interactions that occur between different regions within a functioning human nervous system.
NSCI’s assembloid strategy is designed to address this challenge.
By combining organoids representing different brain regions, researchers can create more complex biological systems in which cells and tissues from different areas interact. These interactions may be important for understanding neurological disorders and determining how potential therapies affect multiple areas of the brain.
The Multi-Brain Region Assembloid Approach
The project recognized by the NIH focuses on creating multi-brain region assembloids that can model complex interactions within the human nervous system.
Researchers at NSCI have developed expertise in producing brain region-specific organoids from human stem cells. These organoids can be engineered or developed to reflect particular regions or characteristics of the human brain.
The next step is to combine these individual models into functional assembloids.
This approach could provide researchers with a more comprehensive experimental system for studying processes that cannot be adequately captured using isolated cell cultures or single-region organoids.
The resulting models could potentially be used to investigate how different areas of the brain communicate, how neurological diseases affect multiple brain regions, and how therapeutic compounds influence these interactions.
Because neurological diseases can involve complex networks of cells and brain regions, researchers believe that models capable of reproducing multiple biological interactions could provide valuable information during drug development.
Potential Applications in Drug Development
One of the potential applications of NSCI’s assembloid technology is the evaluation of drug candidates.
Researchers could use these human-relevant models to examine how experimental therapies affect different brain regions and cellular populations. The models could potentially provide information about both therapeutic activity and unwanted biological effects.
This could be particularly valuable in the development of treatments for complex neurological diseases, where conventional laboratory models may not fully reproduce human disease biology.
The technology could also potentially support the identification of promising drug candidates earlier in the development process.
If a compound produces the desired biological response in a human-derived model while demonstrating an acceptable safety profile, researchers may have greater confidence in advancing the candidate toward additional testing.
Conversely, identifying potential problems earlier could help researchers avoid investing significant resources in compounds that are unlikely to perform successfully in humans.
Supporting New Approach Methodologies
The NIH’s Complement-ARIE initiative reflects growing interest in developing technologies that can complement ARIE or, in some applications, replace traditional animal-based research.
New Approach Methodologies encompass a broad range of technologies, including human cell-based systems, organoids, computational models, tissue engineering approaches, and other advanced experimental platforms.
The objective is not simply to eliminate animal studies but to develop research approaches that can provide more predictive information about human biology.
The NIH’s Complement-ARIE RTP Challenge is specifically focused on moving promising NAM technologies toward practical implementation.
By recognizing NSCI’s Multi-Brain Region Assembloid Combinatorial Models project as a Phase 1 winner, the initiative provides visibility to an approach that could contribute to the development of more sophisticated human neurological disease models.
The recognition also reflects the broader shift taking place across biomedical research toward technologies that can capture human-specific biology with increasing precision.
Multidisciplinary Team Leads Project
The NSCI project is being led by Dr. Jeff Stern, director of Translational Research at the Neural Stem Cell Institute.
The multidisciplinary team includes Dr. Sally Temple, Dr. Taylor Bertucci, Steven Lotz, Dr. Catherine Hamann, Dr. Thomas Kiehl, Kristina Roberts, and Dr. Michelle Lewis.
The combination of expertise across stem cell biology, neuroscience, translational research, and model development is expected to support the advancement of the assembloid platform.
Developing complex human brain models requires expertise in generating reliable cell populations, maintaining appropriate cellular characteristics, creating reproducible structures, and evaluating biological responses.
A multidisciplinary research strategy can therefore be important when moving an experimental technology from proof-of-concept studies toward a standardized platform that can eventually be used in drug development.
Improving Predictability in Neurological Research
Neurological diseases represent some of the most challenging areas of biomedical research.
Conditions affecting the brain and nervous system often involve multiple cell types, interconnected brain regions, complex signaling pathways, and disease mechanisms that are difficult to reproduce using simplified laboratory models.
The human brain is also particularly challenging to study directly because access to living human neural tissue is limited.
Human stem cell-derived models offer researchers another way to investigate human neurological biology under controlled laboratory conditions.
NSCI’s assembloid platform could potentially provide a way to examine interactions between multiple brain regions while maintaining a human cellular context.
Such models may help researchers better understand disease mechanisms and evaluate how experimental therapies influence complex neural systems.
The long-term objective is to generate models that are sufficiently reproducible and scalable to become useful tools for pharmaceutical research and therapeutic development.
Scalability Could Support Broader Adoption
Another important aspect of the NSCI project is the potential to produce the models at scale.
For a new research methodology to have a meaningful impact on drug development, it needs to be reproducible and practical for use across multiple experiments.
Scalability could allow researchers to generate larger numbers of assembloid models for screening drug candidates, studying different disease mechanisms, or comparing responses among different biological conditions.
A scalable platform could also support broader adoption by pharmaceutical companies, biotechnology organizations, academic laboratories, and other research institutions.
If validated successfully, the technology could become part of a broader preclinical testing strategy that combines multiple human-relevant approaches to generate more comprehensive information before therapies enter clinical trials.
Recognition From NIH Reflects Broader Industry Momentum
The recognition of NSCI’s work comes as the biomedical research community increasingly explores alternatives and complements ARIE to conventional animal testing.
Advances in stem cell biology, organoid technology, tissue engineering, artificial intelligence, and computational biology are creating new possibilities for studying human disease.
Researchers are increasingly seeking models that can better represent human-specific biology and provide more reliable predictions about how treatments will perform in patients.
The NIH’s support for the development of NAMs reflects this changing research landscape.
For NSCI, recognition through the NIH’s Complement-ARIE RTP Challenge provides additional validation of its approach to developing human brain models.
Dr. Stern said the institute’s goal is to develop human-relevant models that better reflect the complexity of the human nervous system and provide researchers with more predictive tools for evaluating new treatments.
According to Stern, combining multiple brain-region organoids into functional assembloids could help accelerate neurological drug development while contributing to efforts to reduce reliance on animal models.
Potential Impact on Future Drug Discovery
The potential impact of the technology extends beyond individual neurological research projects.
If multi-brain region assembloids can successfully reproduce important aspects of human brain biology, they could become valuable tools throughout the drug development process.
Researchers could potentially use them during early-stage target validation, compound screening, mechanism-of-action studies, toxicity assessments, and translational research.
The models could also be used alongside other human-based technologies to build a more comprehensive picture of how a treatment may behave in humans.
Rather than relying on a single model, future drug development may increasingly use combinations of organoids, human tissue models, computational systems, and other NAMs to assess drug candidates from multiple perspectives.
This integrated approach could potentially improve decision-making before clinical trials and help researchers identify promising treatments more efficiently.
The selection of the Neural Stem Cell Institute as a Phase 1 winner in the NIH Complement-ARIE Reduction to Practice Challenge represents an important milestone in the development of its multi-brain region assembloid technology.
The project combines human stem cell biology and advanced organoid engineering to create more complex models of the human nervous system.
By reproducing interactions between multiple brain regions, NSCI hopes to provide researchers with tools that are more biologically relevant to human neurological disease than conventional simplified laboratory systems.
The technology’s potential scalability could further increase its value for drug discovery and therapeutic development.
As the biomedical industry continues to search for more predictive preclinical models, platforms such as NSCI’s multi-brain region assembloids could become increasingly important. Their development aligns with a broader movement toward human-based research methodologies designed to improve understanding of disease, strengthen confidence in drug candidates, and potentially accelerate the delivery of effective therapies to patients.
The NIH recognition provides further momentum for this work and highlights the growing importance of advanced human-relevant technologies in the future of biomedical research.
About the Neural Stem Cell Institute (NSCI)
The Neural Stem Cell Institute (NSCI) is the first independent, non-profit stem cell research institute in the United States. NSCI is dedicated to harnessing the power of stem cells to understand brain development, uncover mechanisms of central nervous system disease, and develop novel therapeutics to restore function.